公开(公告)号：US20240315220A1

公开(公告)日：2024-09-26

申请号：US18605786

申请日：2024-03-14

Applicant: The Jackson Laboratory ,  Indiana University Research and Technology Corporation

Inventor： Gareth Howell ,  Michael Sasner ,  Gregory Carter ,  Bruce Lamb

IPC: A01K67/0278 ,  C07K14/705 ,  C07K14/775 ,  G01N33/68

CPC classification number: A01K67/0278 ,  C07K14/70503 ,  C07K14/775 ,  G01N33/6896 ,  A01K2217/056 ,  A01K2217/072 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/0312 ,  G01N2500/00

Abstract: Genetically modified mice characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease are provided wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p) operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p.R47H (Trem2p) operably linked to a promoter, such that the mouse expresses human APOE4p and mouse Trem2p. Methods are provided for screening for a compound for use in the treatment of Alzheimer's disease using such genetically modified mice.

公开(公告)号：US12060615B2

公开(公告)日：2024-08-13

申请号：US16285019

申请日：2019-02-25

Applicant: The Johns Hopkins University

Inventor： William G. Nelson ,  Srinivasan Yegnasubramanian ,  Xiaohui Lin ,  Traci J. Speed ,  Zachery Reichert

IPC: A61K31/4184 ,  A61K31/136 ,  A61K31/381 ,  A61K31/404 ,  A61K31/4188 ,  A61K31/4245 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/517 ,  A61K31/519 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/68

CPC classification number: C12Q1/6886 ,  A61K31/136 ,  A61K31/381 ,  A61K31/404 ,  A61K31/4184 ,  A61K31/4188 ,  A61K31/4245 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/517 ,  A61K31/519 ,  G01N33/5011 ,  G01N33/6875 ,  C12Q2600/136 ,  C12Q2600/154 ,  C12Q2600/158 ,  G01N2500/00

Abstract: The present invention provides methods for discovering agents that are effective in reversing epigenetic silencing by inhibiting the interaction of methyl-binding (MBD) proteins with methylated genomic DNA. Also provided are methods for reactivating silenced genes having CpG island hypermethylation along with methods for treatment and prevention of diseases, such as cancer and sickle cell anemia, by administering an agent that modulates methyl-binding domain (MBD) protein-mediated transcriptional repression, thereby increasing gene transcription to prevent or treat disease. Additionally, compounds identified by the present invention useful for treatment and prevention of diseases, such as cancer and sickle cell anemia, are provided.

公开(公告)号：US20240240173A1

公开(公告)日：2024-07-18

申请号：US18529287

申请日：2023-12-05

Applicant: The Board of Trustees of the Leland Stanford Junior University ,  The United States Government as Represented by the Department of Veterans Affairs

Inventor： William H. Robinson ,  Yann Chong Tan ,  Jeremy Sokolove

IPC: C12N15/10 ,  C07K16/00 ,  C07K16/12 ,  G01N33/68

CPC classification number: C12N15/1065 ,  C07K16/00 ,  C07K16/1242 ,  C07K16/1271 ,  G01N33/6854 ,  C07K2317/21 ,  C07K2317/76 ,  G01N2458/10 ,  G01N2500/00

Abstract: Disclosed herein are compositions and methods for sequencing, analyzing, and utilizing samples such as single samples. Also disclosed herein are compositions and methods for matching together two or more sequences from a sample. Also disclosed herein are compositions and methods for expressing and screening molecules of interest.

公开(公告)号：US12038438B2

公开(公告)日：2024-07-16

申请号：US17509933

申请日：2021-10-25

Applicant: Bio-Rad Laboratories, Inc.

Inventor： Darren R. Link ,  Michael L. Samuels

IPC: G01N33/573 ,  B01F23/41 ,  B01F25/433 ,  B01F33/3011 ,  B01J19/00 ,  B01L3/00 ,  C12Q1/25 ,  C12Q1/6804 ,  C12Q1/6818 ,  C12Q1/6827 ,  C12Q1/6851 ,  C40B40/04 ,  C40B50/08 ,  C40B60/10 ,  G01N33/50 ,  G01N33/542 ,  G01N33/58 ,  B01L7/00 ,  G01N21/64

CPC classification number: G01N33/573 ,  B01F23/41 ,  B01F25/433 ,  B01F25/4336 ,  B01F33/3011 ,  B01J19/0046 ,  B01L3/502761 ,  C12Q1/25 ,  C12Q1/6804 ,  C12Q1/6818 ,  C12Q1/6827 ,  C12Q1/6851 ,  C40B40/04 ,  C40B50/08 ,  C40B60/10 ,  G01N33/5008 ,  G01N33/542 ,  G01N33/582 ,  B01J2219/00286 ,  B01J2219/00351 ,  B01J2219/00418 ,  B01J2219/00479 ,  B01J2219/00576 ,  B01J2219/00585 ,  B01J2219/0059 ,  B01J2219/00592 ,  B01J2219/00599 ,  B01J2219/0065 ,  B01J2219/00657 ,  B01J2219/00664 ,  B01J2219/00702 ,  B01J2219/0072 ,  B01J2219/00722 ,  B01J2219/0074 ,  B01J2219/00743 ,  B01L7/52 ,  B01L2200/027 ,  B01L2300/0636 ,  B01L2300/0645 ,  B01L2300/0654 ,  B01L2300/0681 ,  B01L2300/0864 ,  B01L2300/0867 ,  B01L2400/0415 ,  B01L2400/0487 ,  G01N21/6428 ,  G01N21/6445 ,  G01N2500/00

Abstract: The invention generally relates to methods for quantifying an amount of enzyme molecules. Systems and methods of the invention are provided for measuring an amount of target by forming a plurality of fluid partitions, a subset of which include the target, performing an enzyme-catalyzed reaction in the subset, and detecting the number of partitions in the subset. The amount of target can be determined based on the detected number.

公开(公告)号：US20240041831A1

公开(公告)日：2024-02-08

申请号：US18314623

申请日：2023-05-09

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ,  New York Medical College

Inventor： John R. Falck ,  Michal L. Schwartzman ,  Victor Garcia

IPC: A61K31/41 ,  A61K47/54 ,  A61P13/12 ,  A61K31/197 ,  A61K31/201 ,  C07C59/42 ,  C07C233/49 ,  C07C247/12 ,  C07D257/06 ,  C40B40/04 ,  C07K14/72 ,  C40B30/04 ,  G01N33/92 ,  C07D257/04

CPC classification number: A61K31/41 ,  A61K47/542 ,  A61P13/12 ,  A61K31/197 ,  A61K31/201 ,  C07C59/42 ,  C07C233/49 ,  C07C247/12 ,  C07D257/06 ,  C40B40/04 ,  C07K14/723 ,  C40B30/04 ,  G01N33/92 ,  C07D257/04 ,  G01N2333/705 ,  G01N2500/00

Abstract: The present invention concerns compounds and their use to treat cardiovascular disease, renal disease, thrombic disease, stroke, metabolic syndrome, cell proliferation, and ischemic cardiovascular disorders. Compounds of the present invention display significant potency as antagonists of 20-hydroxyeicosatetraenoic acid (20-HETE), and function as anti-hypertensive, anti-inflammatory, or anti-growth agents.

公开(公告)号：US20190094226A1

公开(公告)日：2019-03-28

申请号：US16199822

申请日：2018-11-26

Applicant: Raindance Technologies, Inc.

Inventor： Darren Roy Link ,  Michael L. Samuels

IPC: G01N33/573 ,  B01L3/00 ,  C12Q1/6804 ,  C12Q1/25 ,  C12Q1/6818 ,  G01N33/58 ,  G01N33/542 ,  C40B40/04 ,  C40B50/08 ,  B01F13/00 ,  B01F5/06 ,  B01J19/00 ,  G01N33/50 ,  B01F3/08 ,  C40B60/10 ,  C12Q1/6827 ,  B01L7/00 ,  G01N21/64

CPC classification number: G01N33/573 ,  B01F3/0807 ,  B01F5/0646 ,  B01F5/0653 ,  B01F13/0062 ,  B01J19/0046 ,  B01J2219/00286 ,  B01J2219/00351 ,  B01J2219/00418 ,  B01J2219/00479 ,  B01J2219/00576 ,  B01J2219/00585 ,  B01J2219/0059 ,  B01J2219/00592 ,  B01J2219/00599 ,  B01J2219/0065 ,  B01J2219/00657 ,  B01J2219/00664 ,  B01J2219/00702 ,  B01J2219/0072 ,  B01J2219/00722 ,  B01J2219/0074 ,  B01J2219/00743 ,  B01L3/502761 ,  B01L7/52 ,  B01L2200/027 ,  B01L2300/0636 ,  B01L2300/0645 ,  B01L2300/0654 ,  B01L2300/0681 ,  B01L2300/0864 ,  B01L2300/0867 ,  B01L2400/0415 ,  B01L2400/0487 ,  C12Q1/25 ,  C12Q1/6804 ,  C12Q1/6818 ,  C12Q1/6827 ,  C40B40/04 ,  C40B50/08 ,  C40B60/10 ,  G01N21/6428 ,  G01N21/6445 ,  G01N33/5008 ,  G01N33/542 ,  G01N33/582 ,  G01N2500/00

Abstract: The invention generally relates to methods for quantifying an amount of enzyme molecules. Systems and methods of the invention are provided for measuring an amount of target by forming a plurality of fluid partitions, a subset of which include the target, performing an enzyme-catalyzed reaction in the subset, and detecting the number of partitions in the subset. The amount of target can be determined based on the detected number.

公开(公告)号：US20180353913A1

公开(公告)日：2018-12-13

申请号：US16105042

申请日：2018-08-20

Applicant: Raindance Technologies, Inc.

Inventor： Darren Roy Link ,  Brian Hutchison ,  Michael L. Samuels ,  Michael Weiner

IPC: B01F3/08 ,  G01N33/50 ,  C40B50/08 ,  C40B40/04

CPC classification number: B01F3/0807 ,  B01F5/0646 ,  B01F5/0653 ,  B01F13/0062 ,  B01F2215/0037 ,  B01J19/0046 ,  B01J2219/00286 ,  B01J2219/00351 ,  B01J2219/00418 ,  B01J2219/00479 ,  B01J2219/00576 ,  B01J2219/00585 ,  B01J2219/0059 ,  B01J2219/00592 ,  B01J2219/00599 ,  B01J2219/0065 ,  B01J2219/00657 ,  B01J2219/00664 ,  B01J2219/00702 ,  B01J2219/0072 ,  B01J2219/00722 ,  B01J2219/0074 ,  B01J2219/00743 ,  B01L3/502761 ,  B01L7/52 ,  B01L2200/027 ,  B01L2300/0636 ,  B01L2300/0645 ,  B01L2300/0654 ,  B01L2300/0681 ,  B01L2300/0864 ,  B01L2300/0867 ,  B01L2400/0415 ,  B01L2400/0487 ,  C40B40/04 ,  C40B50/08 ,  G01N15/1459 ,  G01N33/5008 ,  G01N2015/1006 ,  G01N2500/00 ,  Y02A90/26

Abstract: The present invention generally relates to droplet libraries and to systems and methods for the formation of libraries of droplets. The present invention also relates to methods utilizing these droplet libraries in various biological, chemical, or diagnostic assays.

公开(公告)号：US20180320146A1

公开(公告)日：2018-11-08

申请号：US16030259

申请日：2018-07-09

Applicant: THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY

Inventor： Antonius G.P. Oomens

IPC: C12N7/00 ,  C07K14/005 ,  C12Q1/06

CPC classification number: C12N7/00 ,  A61K2039/5254 ,  A61K2039/5258 ,  C07K14/005 ,  C12N2760/18511 ,  C12N2760/18522 ,  C12N2760/18523 ,  C12N2760/18534 ,  C12N2760/18562 ,  C12Q1/06 ,  G01N2333/115 ,  G01N2500/00

Abstract: Highly antigenic yet safe vaccines against diseases caused by Paramyxoviridae viruses such as respiratory syncytial virus (RSV) are provided. The vaccines comprise attenuated Paramyxoviridae viruses with high antigenicity but which display impaired cell-to-cell transmission as a result of genetic manipulation of the gene encoding the matrix (M) protein. In the viruses, the M protein is absent or mutated to a less active form. Screening or assay systems and methods for evaluating the infectivity of mutant M proteins anf for identifying suitable M candidates for live-attenuated vaccine virus and VLP production, are also provided.

公开(公告)号：US20180291435A1

公开(公告)日：2018-10-11

申请号：US16012280

申请日：2018-06-19

Applicant: The Children's Medical Center Corporation ,  The United States of America, As Represented by the Secretary, Department of Health & Human Servic

Inventor： Anjana Rao ,  Mamta Tahiliani ,  Kian Peng Koh ,  Suneet Agarwal ,  Aravind Iyer

IPC: C12Q1/6827 ,  G01N33/574 ,  C12Q1/26 ,  C12Q1/6886 ,  C12Q1/6869 ,  C12N5/0783 ,  C12N15/873 ,  C12N5/074 ,  C12Q1/6806 ,  G01N33/53 ,  C12N9/02 ,  C12N5/00 ,  G01N33/50

CPC classification number: C12Q1/6827 ,  C12N5/0018 ,  C12N5/0607 ,  C12N5/0637 ,  C12N5/0696 ,  C12N9/0071 ,  C12N15/873 ,  C12N2501/15 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/606 ,  C12N2501/70 ,  C12N2501/71 ,  C12N2501/999 ,  C12N2506/1307 ,  C12N2506/1353 ,  C12N2510/00 ,  C12Q1/26 ,  C12Q1/6806 ,  C12Q1/6869 ,  C12Q1/6886 ,  C12Q2521/531 ,  C12Q2522/10 ,  C12Q2537/164 ,  C12Q2600/154 ,  G01N33/5011 ,  G01N33/5308 ,  G01N33/57426 ,  G01N33/57484 ,  G01N33/57496 ,  G01N2500/00

Abstract: The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.

公开(公告)号：US20180267051A1

公开(公告)日：2018-09-20

申请号：US15921371

申请日：2018-03-14

Applicant: Omeros Corporation

Inventor： Brian F. O'Dowd ,  Susan R. George

IPC: G01N33/68 ,  G01N33/50 ,  C07K14/705 ,  C07K14/71 ,  C07K14/72 ,  G01N33/92

CPC classification number: G01N33/68 ,  C07K14/705 ,  C07K14/70571 ,  C07K14/71 ,  C07K14/723 ,  C07K2319/09 ,  C07K2319/60 ,  G01N33/5008 ,  G01N33/5035 ,  G01N33/5044 ,  G01N33/5058 ,  G01N33/6803 ,  G01N33/6863 ,  G01N33/92 ,  G01N2333/71 ,  G01N2333/72 ,  G01N2333/726 ,  G01N2458/00 ,  G01N2500/00

Abstract: A method for screening compounds for their ability to interact with transmembrane proteins is provided. Also provided is a method for determining whether proteins such as transmembrane proteins are able to oligomerise.